Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Almirall Will Sell Basilea's Eczema Drug In 10 European Markets, Plus Mexico

This article was originally published in The Pink Sheet Daily

Executive Summary

The company's distribution agreement with Almirall does not change Basilea's 2010 sales guidance for its eczema drug Toctino, execs said.

You may also be interested in...

Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership

Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements

Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up

Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts